Forrester To Recognise B2B Return On Integration Honours And B2B Programmes Of The Year Awards Winners At B2B Summit EMEA 2025
3.9.2025 12:00:00 EEST | Business Wire | Press release
Forrester (Nasdaq: FORR) will recognise Thoughtworks as the 2025 recipient of its B2B Return On Integration (ROI) Honours at B2B Summit EMEA, taking place 6–8 October 2025 in London. The organisation will be recognised for optimising its go-to-market (GTM) approach to improve client retention and expansion by introducing AI-enabled analysis and reporting. Forrester will also honour this year’s B2B Programmes Of The Year (POY) Awards winner, AVEVA, for aligning its marketing, sales, and customer success functions to deliver and scale personalised, insight-driven experiences through its account-based marketing (ABM) strategy. These awards recognise firms that prove alignment rooted in customer value and growth can deliver tangible business outcomes.
B2B Summit EMEA is the premier event for B2B marketing and sales leaders to access new research, proven frameworks, and best practices that advance cross-functional alignment. The programme equips leaders with the tools needed to navigate shifting buyer expectations, the rising influence of AI, and ongoing economic uncertainty.
This year’s B2B ROI Honours winner, Thoughtworks, a global technology consultancy, enhanced its go-to-market efforts by launching a multi-agent marketing insights application built on a martech stack and data architecture reengineered for agents. This application provides real-time reporting with a conversational generative AI interface, based on a unified key performance indicator framework. In its keynote session, Thoughtworks will discuss how it utilised Forrester’s frameworks and research that enabled a shift toward contextual genAI-powered reporting and insights agents. As a result, the GTM organisation is more tightly aligned to the company’s growth priorities, achieving higher win rates and measurable gains in retention and client expansion.
“Like most companies, we relied on manual reporting via CRM systems and dashboards to drive marketing ROI,” said Julie Woods-Moss, chief marketing officer at Thoughtworks. “Now, we operate with AI-powered real-time performance data and reasoning. Rewiring our tech stack for agents and rearchitecting our data was an important first step to building an agentic marketing organisation. Conversational genAI enables marketers to have both real-time data and insightful reasoning. Early benefits include improved win rates, buying group expansion, and better allocation of resources. We are continually looking for ways to improve our go-to-market performance, and it is encouraging to see the rapid adoption of AI agents across marketing at Thoughtworks.”
The B2B POY Awards winner, AVEVA, will also discuss its shift from being a fragmented marketing organisation to operating as a fully integrated ABM personalisation engine that has transformed enterprise account engagement.
“Thoughtworks and AVEVA exemplify how disciplined cross-functional alignment translates into measurable business impact,” said Paul Ferron, VP and research director at Forrester. “At B2B Summit EMEA, attendees will hear how these leaders are reshaping their B2B strategy for growth during this era of volatility.”
Resources:
- Register to attend B2B Summit EMEA.
- Follow Forrester on LinkedIn and #ForrB2BSummit for updates.
- View the full agenda and speakers.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We empower leaders in technology, customer experience, digital, marketing, sales, and product functions to be bold at work and accelerate growth through customer obsession. Our unique research and continuous guidance model helps executives and their teams achieve their initiatives and outcomes faster and with confidence. To learn more, visit Forrester.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250903298055/en/
Contacts
Press:
Hannah Segvich
hsegvich@forrester.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom